Veradermics, Inc Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Veradermics, Inc stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $243.00K, a 88.37% increase year-over-year.
- Veradermics, Inc stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $11.00K.
- Veradermics, Inc stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $129.00K.
- Veradermics, Inc stock issued during period, value, stock options exercised for fiscal 2025 was $156.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $243.00K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $11.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $156.00K 10-K · filed 2026-03-30 | |
| 2025-06-30 | $129.00K 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |